SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion

The company is advancing a CNS-focused portfolio with strong growth in ADHD and Parkinson's products, overcoming supply challenges and expanding through strategic M&A. The pipeline features innovative treatments for depression and epilepsy, while a merger with Indivior aims to accelerate growth and…